AstraZeneca’s durvalumab was granted FDA orphan designation for the treatment of gastric cancer, including gastroesophageal junction cancer, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Unusually active option classes on open October 18th
- Meharry Medical College, partners launch Together for CHANGE initiative
- Sophia Genetics announces collaboration with MSK Cancer Center and AstraZeneca
- AstraZeneca says Soliris approved in China for treatment of adults with NMOSD
- Johnson & Johnson (NYSE:JNJ) Slips despite Cancer Drug Win